A Noncanonical
MET
Exon 14 Splice‐Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib
Hyung‐Joo Oh, Yoo‐Duk Choi, Yoon‐La Choi, Ha‐Young Park, Joon‐Young Yoon, Jang‐Hyeon Kim, Jung‐Hwan Lim, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim ABSTRACT
MET exon 14 skipping is an actionable oncogenic driver in non–small cell lung carcinoma (NSCLC); however, noncanonical splice‐region variants are frequently classified as variants of unknown significance (VUS), which may result in missed therapeutic opportunities and highlight limitations in current DNA next‐generation sequencing (NGS) reporting criteria. We report a patient with pulmonary sarcomatoid carcinoma harboring a noncanonical MET splice donor–proximal indel (c.3022_3028 + 13delinsA), initially interpreted as a VUS, who achieved a rapid and durable response to capmatinib. Subsequent RNA sequencing and droplet digital PCR (ddPCR) confirmed MET exon 14 skipping, supporting the value of orthogonal transcript‐level validation for exon‐adjacent variants.